Adverse Drug Reactions of Anti-thyroid Drugs and Effects of 131I Replacement Therapy in Patients with Hyperthyroidism

doi:10.19803/j.1672-8629.2021.05.14

Abstract

Abstract: Objective To investigate the clinical manifestations, latency, ADR monitoring,and treatment of adverse reactions related to anti-thyroid drugs（ATD）and the clinical effect of ¹³¹ I replacement therapy so as to provide individualized treatment for patients with hyperthyroidism and reference for safer ATD treatment. Methods The clinical data on 119 patients with hyperthyroidism hospitalized due to ADT-induced ADR between June 1, 2017 to May 31, 2019 was retrospectively analyzed. Patients' age, gender, involved organs and systems, types and clinical manifestations of ADR, incubation of ADR, treatments and treatment outcomes were statistically analyzed. The clinical efficacy of ¹³¹I in these patients was also evaluated. Results 79% of the patients developed ADR within one month of medication. ADR occurred as shortly as one day after medication manifested by rashes and myalgia and as late as two years after medication, with leucopenia as the symptom. The highest incidence of ADRs was attributed to the hepatobiliary system damage (MMI 52.78%, PTU 66.67%), blood system damage (MMI 30.56%, PTU 41.67%), and skin and accessory system damage (MMI 19.44%,PTU 8.33%). After ¹³¹I was applied to these patients, the difference in indicators of serum TSH, T3 and T4 was statistically significant (P<0.05).The effective rate of treatment was as high as 93.2%, and there was some chance of long-term hypothyroidism. Conclusion Drugs should be rationally selected according to the characteristics of different ATD treatments. Blood routine indexes, liver function, thyroid function and other indicators should be checked regularly during the treatment to prevent ADRs and ensure the safe use of drugs for patients. ¹³¹I treatment has significant efficacy and is quite safe in patients with hyperthyroidism who develop adverse reactions to ATD treatment.

Key words: anti-thyroid drugs, adverse drug reactions, treatment selection, ¹³¹I treatment

CLC Number:

R969.3

MA Yini, ZHANG Lixiang, ZHANG Zhetao, WANG Xiaoyu, SHI Tianlu. Adverse Drug Reactions of Anti-thyroid Drugs and Effects of ¹³¹I Replacement Therapy in Patients with Hyperthyroidism[J]. Chinese Journal of Pharmacovigilance, 2021, 18(5): 469-472.

References

[1] Kahaly GJ,Bartalena L,Hegedüs L,et al.2018 european thyroid association guideline for the management of graves' hyperthyroidism.[J].European Thyroid Journal,2018,7(4):167-186.
[2] Bahn RS,Burch HB,Cooper DS,et al.Hyperthyroidism and other causes of thyrotoxicosis:management guidelines of the american thyroid association and american association of clinical endocrinologists[J].Endocrine Practice,2011,17(3):456-520.
[3] Gao HW.The efficacy and safety of anti-thyroid drugs in treatment of hyperthyroidism[J].Drug Evaluation(药品评价),2015,12(9):35-39.
[4] Chinese society of Endocrinology,The compilation group of chinese guidelines for the diagnosis and treatment of thyroid diseases.chinese guidelines for the diagnosis and treatment of thyroid diseases[J].Chinese Journal of Internal Medicine(中华内科杂志),2007,46(10):876-882.
[5] Mehmood R,Khan MS,Hussain S,et al.Monitoring and evaluation of thyroid function tests,Serum electrolytes and creatinine levels before and after 131I therapy[J].Endocrine,Metabolic &Immune Disorders Drug Targets,2019,25(8):163-164.
[6] Zhang YF.Analysis of the sex hormone abnormali in female patients with thyroid dysfunction[D].Zhengzhou:Zhengzhou University,2013.
[7] Peng LL,Liu W,Tang R,et al.Literature analysis of adverse drug reactions-events induced by thiamazole[J].Chinese Journal of Pharmacovigilance(中国药物警戒),2018,15(7):404-410.
[8] National Center for ADR Monitoring,China.Pharmacovigilance information[J].Chinese Journal of Pharmacovigilance(中国药物警戒),2009,6(10):637-639.
[9] Li XS,Jin SS,Fan YJ,et al.Association of HLA-C*03:02 with methimazole-induced liver injury in graves' disease patients[J].Biomedicine &Pharmacotherapy,2019,117(9):109905.
[10] Sun MT,Tsai CH,Shih KC.Antithyroid drug-induced agranu-locytosis[J].J Chin Med Assoc,2009,72(8) :438-441.
[11] Ge JB,Xyu YJ.Internal Medicine (内科学)[M].8th ed.Beijing:People's Medical Publishing House,2013:416-418,685-690.
[12] Ibanez L,Vidal X,Ballarin E,et al.Population-based drug-induced agranulocytosis[J].Arch Intern Med,2005,164(8) :869-874.
[13] Chen PL,Shih SR,Wang PW,et al.Genetic determinants of antithyroid drug-induced agranulocytosis by human leukocyte antigen genotyping and genome-wide association study[J].Nat Commun,2015(6) :7633.
[14] Si YT,Xue YM.Countermeasures analysis for adverse effects of antithyroid drugs[J].Drug Evaluation(药品评价),2013,10(23):18-22.
[15] Pan CL.Comparison of adverse reactions and clinical safety between meiliazole and prothiouracil in the treatment of hyperthyroidism[J].World's Latest Medicine Information(世界最新医学信息文摘),2016,16(74):100-101.
[16] Huang JW,Zheng QL,Xiao PY,et al.Pharmacoeconomics of 3 Drugs in the treatment of hyperthyroidism[J].China Pharmacy(中国药房),2008 (11):805-807.
[17] Shi X.Application and efficacy evaluation of methimazole combined with propranolol in patients with hyperthyroidism[J].Psychologies(心理月刊),2019,14(14):147-148.
[18] Gianetti E,Russo L,Orlandi F,et al.Pregnancy outcome in women treated with methimazole or propylthiouracil during pregnancy[J].Journal of Endocrinological Investigation,2015,38(9):977-985.
[19] Xu YM.Comparison of short-term and long-term efficacy of 131I and antithyroid drugs in the treatment of hyperthyroidism[J].Modern Diagnosis and Treatment(现代诊断与治疗),2017,28(21):3975-3976.
[20] Li N,Zhang XM,Zhi TT,et al.Effects of low-dose ¹³¹I combined with methimazole and prothiouracil on serum CT,PTH and BGP levels in patients with hyperthyroidism[J].Chinese Journal of Clinical Rational Drug Use(临床合理用药杂志),2015,8(31):43-44.
[21] Chen HY.¹³¹I plus drug hyperthyroidism comprehensive feasibility study for the treatment of hyperthyroidism[J].Henan Journal of Preve-ntive Medicine(河南预防医学杂志),2019,30(5):329-330,334.
[22] Shi GM,Xu Q,Zhu CY,et al.Influence of propylthiouracil and methimazole pre-treatment on the outcome of iodine-131 therapy in hyperthyroid patients with graves' disease.[J].The Journal of International Medical Research,2009,37(2):576-582.
[23] Federico G,Boni G,Fabiani B,et al.No evidence of chromosome damage in children and adolescents with differentiated thyroid carcinoma after receiving ¹³¹I radiometabolic therapy,as evaluated by micronucleus assay and microarray analysis[J].European Journal of Nuclear Medicine and Molecular Imaging,2008,35(11):2113-2121.

Adverse Drug Reactions of Anti-thyroid Drugs and Effects of ¹³¹I Replacement Therapy in Patients with Hyperthyroidism

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

[1]	CAO Guiping, DENG Linlin, ZHU Ganhong, LU Ying, MA Shuang, CHEN Linlin, Liu Lili. One case of severe liver injury caused by Tianma Shouwu tablets [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 216-218.
[2]	GUO Longxin, GAO Yunjuan, WU Chengzhao, LONG Minjuan, ZHU Shengkai, SONG Haibo, ZHAO Xu, XIAO Xiaohe. Exploring new risk signals and susceptibility factors of traditional Chinese medicine-induced hepatotoxicity based on big data from adverse reaction monitoring [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 15-19.
[3]	JIANG Wenshuo, YANG Li. Adverse drug reaction among 694 patients in an epilepsy physician-pharmacist joint clinic [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 102-106.
[4]	CHEN Huayan, JIANG Dongbo, GUO Chunlian, YANG Jiaqi, LI Yuxin, CAI Weiming. Safety of nirmatrelvir/ritonavir in the treatment of novel coronavirus infections [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 107-110.
[5]	LI Xiaozhu, WANG Qiang, PANG Yu, ZHANG Yijing. Management of individual adverse drug reaction reports [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 975-977.
[6]	LIU Wendong, CUI Huanhuan, WANG Xiaohan, SU Xian, WANG Haixue. Status and thinking of Parmacovigilance regulatory system during clinical trials of the pediatric drug in China [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1002-1006.
[7]	ZANG Tianying, LIU Bingyang, TANG Xiaojun. Differentiation of vancomycin induced anaphylactoid and anaphylactic reactions [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1078-1080.
[8]	CHANG Yongzhuo, LI Ji, ZHANG Xiaoyan, ZHOU Chaofan. One case of abnormal uterine bleeding caused by Baofukang suppository [J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 935-938.
[9]	WANG Shuwei, YIN Jinjun, WANG Bing, SONG Caiping, YANG Fujun. Axitinib tablets combined with toripalimab injection in the treatment of renal cancer-induced central retinal artery occlusion: a case report [J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 825-828.
[10]	ZHENG Yi, LUO Xiao, ZHANG Pengpeng, LIU Yongmei, YE Xiaofei, GUO Xiaojing, CHEN Xia, HE Jia. Adverse reactions of immune checkpoint inhibitor myocarditis based on active monitoring system [J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 634-638.
[11]	LI Tan, ZHANG Yang, ZHANG Wangde, WANG Yun. Efficacy and safety of different analgesia drugs in the treatment of lower extremity ischemic pain [J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 680-683.
[12]	CHEN Chongze, LI Jie, KUANG Lian, TAN Xuewen, LIU Minhui, LIU Xi, ZHENG Yanchai, JIN Hongtao. Characterization of adverse reactions associated with drug-induced liver injury in 448 inpatients [J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 697-704.
[13]	. Annual report of national adverse drug reaction monitoring (2022) [J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 712-719.
[14]	CHEN Cheng, DENG Li, LIU Songqing, DU Qian, XI Xin. Analysis of reports of allergic shock in Chongqing between 2015 and 2020 [J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 460-464.
[15]	OUYANG Ying, ZHONG Changxin, XIA Chunhua, NIE Jungang, ZHOU Ying. One case of breast hyperplasia caused by digoxin tablets [J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 346-347.